Achilles Therapeutics Plc ADR [NASDAQ: ACHL] closed the trading session at $0.94.
The stocks have a year to date performance of 5.74 percent and weekly performance of 32.39 percent. The stock has been moved at -27.13 percent over the last six months. The stock has performed 27.54 percent around the most recent 30 days and changed 10.35 percent over the most recent 3-months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If compared to the average trading volume of 44.26K shares, ACHL reached to a volume of 33782023 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Achilles Therapeutics Plc ADR [ACHL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ACHL shares is $1.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ACHL stock is a recommendation set at 3.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Achilles Therapeutics Plc ADR shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on April 05, 2024. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Overweight. The new note on the price target was released on April 26, 2021, representing the official price target for Achilles Therapeutics Plc ADR stock. Previously, the target price had yet another raise to $23, while Oppenheimer analysts kept a Outperform rating on ACHL stock.
The Average True Range (ATR) for Achilles Therapeutics Plc ADR is set at 0.06 The Price to Book ratio for the last quarter was 0.33, with the Price to Cash per share for the same quarter was set at 2.31.
ACHL stock trade performance evaluation
Achilles Therapeutics Plc ADR [ACHL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 32.39. With this latest performance, ACHL shares gained by 27.54% in over the last four-week period, additionally sinking by -27.13% over the last 6 months – not to mention a rise of 8.78% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ACHL stock in for the last two-week period is set at 78.74, with the RSI for the last a single of trading hit 86.31, and the three-weeks RSI is set at 71.71 for Achilles Therapeutics Plc ADR [ACHL]. The present Moving Average for the last 50 days of trading for this stock 0.7718, while it was recorded at 0.7574 for the last single week of trading, and 0.9099 for the last 200 days.
Achilles Therapeutics Plc ADR [ACHL]: An insightful look at the core fundamentals
Achilles Therapeutics Plc ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.24 and a Current Ratio set at 8.24.
Earnings per share (EPS) analysis for Achilles Therapeutics Plc ADR [ACHL] stock
With the latest financial reports released by the company, Achilles Therapeutics Plc ADR posted -0.42/share EPS, while the average EPS was predicted by analysts to be reported at -0.4/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.02. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ACHL.
Achilles Therapeutics Plc ADR [ACHL]: Institutional Ownership
The top three institutional holders of ACHL stocks are: SYNCONA PORTFOLIO LTD with ownership of 11.09 million shares, which is approximately 27.5236%. FCPM III SERVICES B.V., holding 2.39 million shares of the stock with an approximate value of $$1.95 million in ACHL stocks shares; and FCPM III SERVICES B.V., currently with $$1.31 million in ACHL stock with ownership which is approximately 3.9921%.
